Skip to main content
Terug
CSPCY logo

CSPC Pharmaceutical Group Limited

Datakwaliteit: 100%
CSPCY
OTC Healthcare Drug Manufacturers - General
€ 4,17
▼ € 0,25 (-5,62%)
Marktkapitalisatie: 12,03B
Ook genoteerd als CHJTF OTC
Dagbereik
€ 4,17 € 4,36
52-Weeksbereik
€ 2,32 € 5,83
Volume
1
50D / 200D Gem.
€ 4,90 / € 4,61
Vorige Slotkoers
€ 4,41

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 2,6 0,3
P/B 0,4 2,9
ROE % 14,1 3,7
Net Margin % 14,9 3,8
Rev Growth 5Y % 1,0 10,0
D/E 0,0 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 € 0,00
€ 0,00 – € 0,00
 270 B 0

Belangrijkste Punten

Revenue grew 1,04% annually over 5 years — modest growth
Earnings declined -21,59% over the past year
ROE of 14,07% — decent returns on equity
Debt/Equity of 0,02 — conservative balance sheet
Generating 1,86B in free cash flow
P/E of 2,61 — trading at a low valuation

Groei

Revenue Growth (5Y)
1,04%
Revenue (1Y)-10,78%
Earnings (1Y)-21,59%
FCF Growth (3Y)-38,49%

Kwaliteit

Return on Equity
14,07%
ROIC13,07%
Net Margin14,92%
Op. Margin18,50%

Veiligheid

Debt / Equity
0,02
Current Ratio2,27
Interest Coverage130,74

Waardering

P/E Ratio
2,61
P/B Ratio0,37
EV/EBITDA1,01
Dividend Yield0,06%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -10,78% Revenue Growth (3Y) -6,10%
Earnings Growth (1Y) -21,59% Earnings Growth (3Y) -18,27%
Revenue Growth (5Y) 1,04% Earnings Growth (5Y) -2,80%
Profitability
Revenue (TTM) 30,87B Net Income (TTM) 4,61B
ROE 14,07% ROA 10,37%
Gross Margin 69,97% Operating Margin 18,50%
Net Margin 14,92% Free Cash Flow (TTM) 1,86B
ROIC 13,07% FCF Growth (3Y) -38,49%
Safety
Debt / Equity 0,02 Current Ratio 2,27
Interest Coverage 130,74 Dividend Yield 0,06%
Valuation
P/E Ratio 2,61 P/B Ratio 0,37
P/S Ratio 0,39 PEG Ratio -0,53
EV/EBITDA 1,01 Dividend Yield 0,06%
Market Cap 12,03B Enterprise Value 5,76B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 30,87B 34,60B 35,01B 34,19B 29,62B
Net Income 4,61B 5,87B 6,89B 6,88B 5,16B
EPS (Diluted) 1,56 2,00 2,04 1,88 2,04
Gross Profit 21,60B 24,40B 22,73B 25,47B 21,00B
Operating Income 5,71B 7,68B 7,58B 7,66B 6,49B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 44,39B 46,28B 41,77B 42,50B 35,65B
Total Liabilities 10,52B 12,39B 11,46B 9,71B 8,28B
Shareholders' Equity 32,26B 33,20B 29,77B 31,79B 26,48B
Total Debt 507,33M 706,90M 621,48M 102,76M 358,71M
Cash & Equivalents 6,78B 12,02B 11,65B 9,28B 8,65B
Current Assets 21,89B 26,74B 23,96B 20,34B 18,88B
Current Liabilities 9,63B 10,18B 10,14B 8,84B 7,47B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#439 of 827
40
Value Defensive Investing (Benjamin Graham)
#173 of 709
45

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026